3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Cancer, Papillary
1
Lymphatic Metastasis
1
Gliosarcoma
1
Glioblastoma
1
Interventions
Trastuzumab
2
Iodine-131
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
pazopanib
1
mercaptoundecahydrododecaborate
1
copanlisib
1
Vemurafenib
1
Triiodothyronine
1
Surgical Procedures, Operative
1
Spectrum Analysis
1
Rosiglitazone
1
Radiofrequency Ablation
1
Photochemotherapy
1
Paclitaxel
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Imatinib Mesylate
1
Famotidine
1
Docetaxel
1
Congresses as Topic
1
Bortezomib
1
Azacitidine
1
4-boronophenylalanine-fructose
1
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thyroid Cancer, Papillary
×
Spectrum Analysis
×
Clear all
NCT03470259
2024-04-16
TARGET
University Medical Center Groningen
Phase 1
Completed
19 enrolled